FDA, EMA to review AstraZeneca's vandetanib

FDA and the European Medicines Agency (EMA) accepted an NDA and an MAA from AstraZeneca plc (LSE:AZN; NYSE:AZN) for vandetanib to treat advanced medullary thyroid cancer (MTC). FDA granted Priority Re...